PreludeDx’s Post

If there was a particular treatment that worked 94% of the time, would you claim that it was placebo? Unlikely. In 2022, Radiation Oncologists from Spain conducted a prospective trial of 100 patients with osteoarthritis of the hands. They were given low dose radiation therapy (LDRT) and followed for 3,6, and 12 months. Here were the results: ❇️ 94% of the patients reported significant pain reduction ❇️ 70% of patients reported improved functional performance ❇️Responses were evaluated with VAS for pain and VPS for joint functionality ❇️ 50% of the patients had a second course of LDRT. Keep in mind that this is a subset of patients that have historically failed all other conservative management 🤯 Reference: https://lnkd.in/gh6fT5Gw

Unfractionated Heparin 🆚 Low Molecular Weight Heparin One time I had a patient having a STEMI who also had a history of liver failure. I remember being curious as to whether or not heparin would actually be beneficial. Here’s what I found: 👉Heparin works by binding to something called antithrombin floating around in the blood. When activated, antithrombin will go around and bind to factor Xa and (if giving unfractionated heparin) bind to thrombin too. 👉Because antithrombin is produced in the liver, liver failure patients will have very low levels of antithrombin circulating in their system, and with that being the primary mechanism of action for heparin, the efficacy is drastically reduced. 👉Current use of heparin for ACS remains largely supported by anecdotal practice rather than robust clinical trial date

The precise immunological mechanisms involved in clinical responses to bispecific T-cell engagers (TCE) in multiple myeloma (MM) are poorly understood. In a detailed case report, Krzysiek et al. documented that complete response to elranatamab, a B-cell maturation antigen-CD3 bispecific TCE, was associated with clonal CD8+ T-cell expansion in penta-refractory MM. https://lnkd.in/e2kpyKF9

Vancomycin is occassionaly associated with acute kidney injury. Combining Vancomycin with imipenem-cilastatin shows promise of protection against kidney injury in translational rat models. https://ow.ly/y2Pz50S00cG Gwendolyn P. et al. #Vancomycin #Flucloxacillin #ImipenemCilastatin

Treat #BPH patients with a prostate volume ≥ 80cm3 with Water Vapour Therapy Kevin T. McVary, MD, was keen to determine the safety and effectiveness of Water Vapour Therapy in men with large prostate volumes. Discover the results of this systematic review and meta-analysis, including 15 studies (11 retrospective) of 471 men with a prostate volume of at least 80 cm3: https://bit.ly/4bpwQDs #BSCEMEA

New study uncovers how GPCRs, particularly the vasopressin V2 receptor (V2R), continue to signal from internalized compartments, highlighting the role of βarrestin (βarr) and Gβγ in non-canonical endosomal signaling. Discover how these mechanisms can pave the way for innovative therapeutic strategies. Check out the latest GPCR news in the Ecosystem today! You’ll need to register, but don’t worry, it’s Free! ➡️https://bit.ly/4d9yUQ3 #GPCR #DrGPCR

At last week’s NKF meeting, a prominent speaker noted that maximum doses of SGLT2is were not needed in the CV and Renal outcome studies. Of note is that the maximum dose of Dapagliflozin (10mg) was used, while the starting dose of Empagliflozin was used(10mg). The analysis of Empagliflozin’s EMPA-KIDNEY MRI study seems to suggest that there may be a benefit to using higher doses of SGLT2i just as there are to using maximum dose RAASis. Maybe we should retry DAPA CKD with a 5mg dose and EMPA KIDNEY with a 25mg dose and see what happens. Could we look retrospectively at say a Kaiser database on patients on the different dosages? Also, could using pre and post SGLT2i use Fib-4 scores give us similar information?

At Altimmune, we strive to redefine the approach to metabolic health. #Pemvidutide, our investigational dual receptor agonist, is designed for optimal weight management and improved liver function for patients living with #obesity & #MASH. Harnessing the dual benefits of #GLP-1 and #glucagon pathways, pemvidutide has the potential to unlock new health outcomes by simultaneously tackling multiple aspects of #metabolichealth.    Learn more about our therapeutic approach in this recent Everyday Health article by Ross Wollen: https://bit.ly/4cQSpgh 

We herein retain accepted categories of ACS, ST-segment elevation MI, and non-ST segment elevation MI, as important subsets for which revascularization is of proven clinical benefit, as well as new terms like ischemia and MI with non-obstructive coronary arteries. Overall, such a more encompassing nomenclature better aligns, unifies, and harmonizes different pathophysiologic causes of myocardial ischemia and should result in more refined diagnostic and therapeutic approaches targeted to the multiple pathobiological precipitants of angina pectoris, ischemia, and infarction.

Plateletworks effectively determines functional platelet count and true platelet aggregation or inhibition using traditional ADP, Collagen or Arachidonic Acid agonists. All that’s needed is an impedance cell counter and Plateletworks reagent tubes to screen pre-surgical and trauma patients for adequate platelet function and to monitor effects of anti-platelet therapies. https://lnkd.in/eq67e-G